These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 20647856)
1. Is a blood pressure rise the only deleterious off-target effect of cholesterol ester transfer protein inhibitors? Miura S; Saku K J Hypertens; 2010 Aug; 28(8):1614-6. PubMed ID: 20647856 [No Abstract] [Full Text] [Related]
2. [HDL and CETP in atherogenesis]. Pöss J; Böhm M; Laufs U Dtsch Med Wochenschr; 2010 Feb; 135(5):188-92. PubMed ID: 20082258 [TBL] [Abstract][Full Text] [Related]
3. Illuminating HDL--is it still a viable therapeutic target? Rader DJ N Engl J Med; 2007 Nov; 357(21):2180-3. PubMed ID: 17984168 [No Abstract] [Full Text] [Related]
4. HDL: back to the drawing board. Johns Hopkins Med Lett Health After 50; 2007 May; 19(3):1-2. PubMed ID: 17657883 [No Abstract] [Full Text] [Related]
6. Cholesteryl ester transfer protein inhibitors as high-density lipoprotein raising agents. Shinkai H Expert Opin Ther Pat; 2009 Sep; 19(9):1229-37. PubMed ID: 19663630 [TBL] [Abstract][Full Text] [Related]
7. Spotlight on HDL-raising therapies: insights from the torcetrapib trials. Kontush A; Guérin M; Chapman MJ Nat Clin Pract Cardiovasc Med; 2008 Jun; 5(6):329-36. PubMed ID: 18431367 [TBL] [Abstract][Full Text] [Related]
8. Effect of cholesteryl ester transfer protein inhibitor on vitamin E transport should be studied. Masterjohn C Am Heart J; 2009 Jul; 158(1):e11; author reply e13. PubMed ID: 19540377 [No Abstract] [Full Text] [Related]
9. The pharmacology and off-target effects of some cholesterol ester transfer protein inhibitors. Vergeer M; Stroes ES Am J Cardiol; 2009 Nov; 104(10 Suppl):32E-8E. PubMed ID: 19895942 [TBL] [Abstract][Full Text] [Related]
13. Lessons learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. Barter P Am J Cardiol; 2009 Nov; 104(10 Suppl):10E-5E. PubMed ID: 19895939 [TBL] [Abstract][Full Text] [Related]
14. Cholesteryl ester transfer protein inhibitors in the treatment of dyslipidemia: a systematic review and meta-analysis. Li C; Zhang W; Zhou F; Chen C; Zhou L; Li Y; Liu L; Pei F; Luo H; Hu Z; Cai J; Zeng C PLoS One; 2013; 8(10):e77049. PubMed ID: 24204732 [TBL] [Abstract][Full Text] [Related]
15. Cholesteryl ester transfer protein (CETP) inhibitors: is there life after torcetrapib? Neeli H; Rader DJ Cardiol Clin; 2008 Nov; 26(4):537-46. PubMed ID: 18929230 [TBL] [Abstract][Full Text] [Related]
16. Learning lessons from Pfizer's $800 million failure. Nat Rev Drug Discov; 2011 Mar; 10(3):163-4. PubMed ID: 21358723 [No Abstract] [Full Text] [Related]
17. Is high HDL cholesterol always good? Olsson AG Ann Med; 2009; 41(1):11-8. PubMed ID: 19085339 [TBL] [Abstract][Full Text] [Related]
18. New drug fizzles at raising HDL. Tried-and-true strategies are still excellent ways to boost good cholesterol. Harv Heart Lett; 2007 Mar; 17(7):1-2. PubMed ID: 17378073 [No Abstract] [Full Text] [Related]
19. Torcetrapib and coronary events. Dullaart RP; Kobold AC; van Tol A N Engl J Med; 2008 Apr; 358(17):1863; author reply 1863-4. PubMed ID: 18437725 [No Abstract] [Full Text] [Related]
20. Refocusing on use of cholesteryl ester transfer protein inhibitors. Kastelein JJ Am J Cardiol; 2007 Dec; 100(11 A):n47-52. PubMed ID: 18047853 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]